Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy ...
December 06 2017 - 2:00AM
Santhera Pharmaceuticals (SIX:SANN)
,
Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM)
,
Catabasis Pharmaceuticals (NASDAQ:CATB)
and
Duchenne UK are pleased to announce a collaboration to host a
Duchenne Muscular Dystrophy (DMD) Awareness Day today in
London.
The half-day event will feature presentations by
key opinion leaders representing clinical practitioners, industry
professionals and the patient group Duchenne UK. Professor
Dame Kay Davies FRS of the University of
Oxford, Dr Rosaline Quinlivan
MD of the National Hospital for Neurology and
Neurosurgery and Professor Thomas Voit MD of Great
Ormond Street Hospital and University College London will deliver
keynote addresses focusing on the biology and aetiology of the
disease, and the current treatment landscape.
The sponsoring companies will also present on
their respective development programmes for new therapeutic options
for DMD and the future outlook for patients.
Emily Crossley, Co-Founder and joint
Chief Executive Officer of Duchenne UK, and Chair of the event,
commented: “We are excited to be taking part in this
comprehensive DMD awareness day. Duchenne UK is committed to
working globally with industry to fund and accelerate drug
development, and is delighted to be publicly collaborating with
innovative companies such as Summit, Santhera and Catabasis. We are
united in our mission to end Duchenne, and this event will raise
much-needed awareness about this disease and highlight the growing
pipeline of potentially life-changing treatments.”
A live audio webcast of the event will be
available at the following link:
https://edge.media-server.com/m6/p/nacwa6fn. A replay will be
available on the supporting companies’ websites the day after the
event.
For further information of the event, please
contact:DMDevent@consilium-comms.com+44 (0)20 3709 5700
- ENDS -
About Duchenne Muscular
DystrophyDuchenne Muscular Dystrophy is the most common
fatal genetic disease diagnosed in childhood. Children born with
DMD cannot produce the protein dystrophin which is vital for muscle
strength and function. Muscle weakness starts in early childhood.
Many use a wheelchair by around the age of 12. As deterioration
continues it leads to paralysis and early death, often in their
20s. It almost exclusively affects boys. There is no treatment or
cure. In the UK there are around 2,500 boys affected and around
300, 000 worldwide. It is classified as a rare disease.
About CatabasisAt Catabasis
Pharmaceuticals, our mission is to bring hope and life-changing
therapies to patients and their families. Our SMART (Safely
Metabolized And Rationally Targeted) Linker drug discovery platform
enables us to engineer molecules that simultaneously modulate
multiple targets in a disease. We are applying our SMART
LinkerSM platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to
develop additional product candidates. For more information on the
Company's drug discovery platform and pipeline of drug candidates,
please visit www.catabasis.com.
About Duchenne UKDuchenne UK is
a lean, ambitious and highly focused charity with a clear vision:
to fund and accelerate treatments and a cure for Duchenne muscular
dystrophy. The charity has been formed by the coming together of
Joining Jack and Duchenne Children's Trust, the two biggest funders
of research in the UK in the last three years. Its president is HRH
The Duchess of Cornwall. Its patrons include the broadcasters
Krishnan Guru-Murthy and Mary Nightingale, and the sports stars
Owen Farrell, Kris Radlinski and Andy Farrell.
About Santhera Santhera
Pharmaceuticals (SIX:SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of
innovative pharmaceutical products for the treatment of orphan
mitochondrial and neuromuscular diseases. Santhera's lead product
Raxone® (idebenone) is authorized in the European Union, Norway,
Iceland, Liechtenstein and Israel for the treatment of Leber's
hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy
(DMD), Santhera has filed a Marketing Authorization Application in
the European Union and Switzerland for DMD patients with
respiratory function decline who are not taking glucocorticoids. In
collaboration with the U.S. National Institute of Neurological
Disorders and Stroke (NINDS) Santhera is developing Raxone® in a
third indication, primary progressive multiple sclerosis (PPMS),
and another product – omigapil – for congenital muscular dystrophy
(CMD), both also areas of high unmet medical need. For further
information, please visit the Company's website
www.santhera.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
Contact information:
Santhera Pharmaceuticals Sue
Schneidhorst, Head Group Communications Europe: +41 61 906 89 26
US: +1 646 586 2113
Summit Therapeutics Richard
Pye, Senior Director, Corporate Affairs & Communications+44
(0)1235 443 951
Catabasis® Pharmaceuticals,
Inc.Andrea Matthews, Vice President, Corporate Affairs+1
617 349 1971amatthews@catabasis.com
Consilium Strategic
Communications Amber Fennell, Jessica Hodgson, Sukaina
Virji+44 (0)20 3709 5700DMDevent@consilium-comms.com
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2023 to Sep 2024